Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 20:14:1759720X221083541.
doi: 10.1177/1759720X221083541. eCollection 2022.

Osteoporosis in 10 years time: a glimpse into the future of osteoporosis

Affiliations

Osteoporosis in 10 years time: a glimpse into the future of osteoporosis

Giovanni Adami et al. Ther Adv Musculoskelet Dis. .

Abstract

Patients living with osteoporosis are projected to increase dramatically in the next decade. Alongside the forecasted increased societal and economic burden, we will live a crisis of fractures. However, we will have novel pharmacological treatment to face this crisis and, more importantly, new optimized treatment strategies. Fracture liaison services will be probably implemented on a large scale worldwide, helping to prevent additional fractures in high-risk patients. In the next decade, novel advances in the diagnostic tools will be largely available. Moreover, new and more precise fracture risk assessment tools will change our ability to detect patients at high risk of fractures. Finally, big data and artificial intelligence will help us to move forward into the world of precision medicine. In the present review, we will discuss the future epidemiology and costs of osteoporosis, the advances in early and accurate diagnosis of osteoporosis, with a special focus on biomarkers and imaging tools. Then we will examine new and refined fracture risk assessment tools, the role of fracture liaison services, and a future perspective on osteoporosis treatment.

Keywords: bone mineral density; fractures; future perspective; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: G.A. reports personal fees from Theramex and Galapagos outside the submitted work. A.F. reports personal fees from Abiogen, Novartis, and Neopharmed, outside the submitted work. D.G. has received advisory board honoraria, consultancy fees, and/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, and UCB. M.I.D. reports research grants from Pfizer and Horizon. K.G.S. reports research grants from Amgen, Mereo, and Radius and has received consultancy fees from Amgen, outside the submitted work. O.V. has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Ely-Lilly, UCB, AbbVie, MSD, and BMS. M.R. reports advisory board honoraria, consultancy fees, and/or speaker fees from AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Galapagos, Theramex, and UCB, outside the submitted work.

References

    1. Kanis JA, Borgström F, Compston J, et al.. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 2013; 8: 144. - PMC - PubMed
    1. Kanis JA, Norton N, Harvey NC, et al.. SCOPE2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 2021; 16: 82. - PMC - PubMed
    1. Burge R, Dawson-Hughes B, Solomon DH, et al.. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465–475. - PubMed
    1. Wright NC, Looker AC, Saag KG, et al.. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014; 29: 2520–2526. - PMC - PubMed
    1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726–1733. - PubMed

LinkOut - more resources